Control Bionics Limited has entered into an agreement with Double R&D to introduce its NeuroNode Trilogy technology to people with conditions like ALS, cerebral palsy, intellectual disability, stroke and traumatic brain injuries. The CBL initiative will be led by Japanese executive, Erica Kitayama. Control Bionics' technology will be introduced to Japan at KidsFesta in Tokyo on the 16th and 17th of April 2022.

The CBL NeuroNode Trilogy system allows non-verbal people with severely impaired movement to control a computer for speech generation, gaming, email and text, with ease and speed. NeuroNode Trilogy is up to 47% faster than traditional eye-gaze systems with significantly less user fatigue. The initial focus of the CBL/Double R&D partnership will be to train over 30 resellers on the life-changing technology within Double R&D's network.

Double R&D agreement: The material terms of the Double R&D agreement are as follows: The distributor is Double R&D. The agreement appoints Double R&D as the exclusive distributor in Japan of Trilogy products and any other CBL products which CBL and Double R&D subsequently agree (collectively referred to as the Products). Double R&D shall order products from CBL based on the price list included in the agreement. CBL may amend the pricing upon giving 30 days written notice to Double R&D. The term of agreement is continuous and shall terminate upon the terms of the agreement.

Either party may terminate the agreement without cause by giving six months prior written notice, such termination to occur at any date after the second anniversary of the commencement of the agreement. The agreement has standard termination provisions found in commercial agreements of this kind in relation to default as a result of insolvency or breach of the agreement which is not remedied. The agreement has no provision for minimum order purchase quantities, other than a requirement for Double R&D to use best efforts to meet an agreed sales forecast.

The agreement has no conditions precedent.